Quick Answer
Onconetix, Inc. reported Net Income Loss of -$14.03 million for the year ending 2025.
- Onconetix, Inc. showed an increase of +76.1% in Net Income Loss from 2024 to 2025.
- This data is from Onconetix, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$325.8 thousand | Q2 2021: -$792.3 thousand | Q3 2021: -$1.10 million | Q1 2022: -$2.07 million | Q2 2022: -$4.26 million | Q3 2022: -$3.87 million | Q1 2023: -$2.85 million | Q2 2023: -$6.87 million | Q3 2023: -$5.35 million | Q1 2024: -$11.12 million | Q2 2024: -$14.31 million | Q3 2024: -$3.83 million | Q1 2025: -$8.55 million | Q2 2025: -$2.37 million | Q3 2025: -$8.78 million.
- Over the full 5 years of available data (2021 to 2025), Onconetix, Inc.'s Net Income Loss has declined by 310.6%.
- Historical annual values: Fiscal year 2025: -$14.03 million | Fiscal year 2024: -$58.69 million | Fiscal year 2023: -$37.41 million | Fiscal year 2022: -$13.42 million | Fiscal year 2021: -$3.42 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: